Table 1 Baseline characteristics of all study patients (n = 45)
All | Q1 | Q2 | Q3 | Q4 | P | |
|---|---|---|---|---|---|---|
n = 45 | n = 11 | n = 12 | n = 11 | n = 11 | ||
Urinary A-megalin (pmol/g Cr) | ||||||
 Mean ± SD or [Median] | 87.9 ± 46.6 | [36.1] | [76.0] | [95.8] | [150.4] | |
 Range | 1.6–203.6 | 1.6–52.9 | 68.3–79.8 | 79.9–118.9 | 119.8–203.6 | |
Age, years | ||||||
 Mean ± SD | 64.6 ± 8.2 | 62.1 ± 8.9 | 65.8 ± 4.9 | 65.5 ± 8.4 | 64.8 ± 10.3 | 0.702 |
Sex, n (%) | 0.399 | |||||
 Female | 9 (20.0) | 3 (27.3) | 4 (33.3) | 1 (9.1) | 1 (9.1) | |
 Male | 36 (80.0) | 8 (72.7) | 8 (66.7) | 10 (90.9) | 10 (90.9) | |
Body height, cm | ||||||
 Mean ± SD | 163.9 ± 7.2 | 165.0 ± 6.9 | 161.3 ± 6.0 | 165.2 ± 7.0 | 164.5 ± 8.9 | 0.528 |
Body weight, kg | ||||||
 Mean ± SD | 57.7 ± 10.1 | 60.2 ± 10.2 | 59.9 ± 12.8 | 54.3 ± 10.6 | 56.0 ± 4.9 | 0.437 |
Smoking status, n (%) | 0.527 | |||||
 Current/former | 40 (88.9) | 10 (90.9) | 10 (83.3) | 11 (100) | 9 (81.8) | |
 Never | 5 (11.1) | 1 (9.1) | 2 (16.7) | 0 (0.0) | 2 (18.2) | |
Baseline therapies, n (%) | ||||||
 RAS inhibitors | 10 (22.2) | 3 (27.3) | 2 (16.7) | 4 (36.3) | 1 (9.1) | 0.457 |
 NSAIDs | 22 (48.9) | 5 (45.5) | 5 (45.5) | 4 (36.3) | 8 (72.7) | 0.340 |
Baseline comorbidity, n (%) | ||||||
 Hypertension | 20 (44.0) | 3 (27.3) | 9 (75.0) | 5 (45.5) | 3 (27.3) | 0.066 |
 Diabetes | 9 (20.0) | 1 (9.1) | 2 (16.7) | 3 (27.3) | 3 (27.3) | 0.675 |
Initial eGFR (mL/min/1.73 m2) | 0.372 | |||||
 Mean ± SD | 89.7 ± 15.9 | 83.7 ± 16.2 | 87.9 ± 17.1 | 92.9 ± 17.6 | 94.6 ± 11.9 | |
 ≧90 | 24 (53.3) | 4 (36.4) | 8 (66.7) | 6 (54.5) | 6 (54.5) | |
 60–89 | 20 (44.4) | 7 (63.6) | 3 (25.0) | 5 (45.5) | 5 (45.5) | |
 ≦59 | 1 (2.2) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | |
Cisplatin dose (mg/m2) | ||||||
 Mean ± SD | 76.0 ± 5.0 | 73.2 ± 6.8 | 77.5 ± 2.6 | 75.9 ± 5.8 | 77.3 ± 2.6 | 0.143 |
Type of malignancy, n (%) | ||||||
 NSCLC | 33 | |||||
 SCLC | 10 | |||||
 MPM | 2 | |||||